Loncar Cancer Immunotherapy ETF (CNCR): Price and Financial Metrics ETF
CNCR Price/Volume Stats - 7 Best ETFs for the NEXT Bull Market
| Current price | $13.43 | 52-week high | $18.01 |
| Prev. close | $13.29 | 52-week low | $11.68 |
| Day low | $13.23 | Volume | 1,900 |
| Day high | $13.50 | Avg. volume | 7,563 |
| 50-day MA | $12.77 | Dividend yield | N/A |
| 200-day MA | $14.13 |
CNCR Stock Price Chart Interactive Chart >
Loncar Cancer Immunotherapy ETF (CNCR) ETF Bio
The investment objective of the Loncar Cancer Immunotherapy ETF seeks to replicate the Loncar Cancer Immunotherapy Index. The index was developed by a top biologist and includes large pharmaceutical and growth-oriented biotechnology firms that are focused on improving cancer treatments.
CNCR ETF Info
| Issuer | Exchange Traded Concepts |
| Expense Ratio | 0.79% |
| Underlying Index | Loncar Cancer Immunotherapy Index |
| Asset Class | Equity |
| Sector | Health & Biotech ETFs |
| Assets Under Management (AUM) | 16.79M |
| Net Asset Value (NAV) | $13.43 |
| Options? | Yes |
| Total Holdings | 32 |
CNCR Top Holdings
| Symbol | Company | % of Total |
| MRUS | MERUS NV | 0.06% |
| CRSP | CRISPR THERAPEUTICS AG | 0.05% |
| LEGN | LEGEND BIOTECH CORP-ADR | 0.05% |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | 0.04% |
| RAPT | RAPT THERAPEUTICS INC | 0.04% |
| BGNE | BEIGENE LTD-ADR | 0.04% |
| ARGX | ARGENX SE - ADR | 0.04% |
| MRK | MERCK & CO. INC. | 0.04% |
| IMTX | IMMATICS NV | 0.04% |
CNCR Price Returns
| 1-mo | 2.05% |
| 3-mo | 0.00% |
| 6-mo | -10.82% |
| 1-year | -3.21% |
| 3-year | -45.63% |
| 5-year | -48.86% |
| YTD | -2.18% |
| 2022 | -42.31% |
| 2021 | -19.24% |
| 2020 | 36.53% |
| 2019 | 24.22% |
| 2018 | -20.65% |